Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia.

Ghorani E, Kaur B, Fisher RA, Short D, Joneborg U, Carlson JW, Akarca A, Marafioti T, Quezada SA, Sarwar N, Seckl MJ.

Lancet. 2017 Nov 25;390(10110):2343-2345. doi: 10.1016/S0140-6736(17)32894-5. No abstract available.

2.

Complete Serologic Response to Pembrolizumab in a Woman With Chemoresistant Metastatic Choriocarcinoma.

Huang M, Pinto A, Castillo RP, Slomovitz BM.

J Clin Oncol. 2017 Sep 20;35(27):3172-3174. doi: 10.1200/JCO.2017.74.4052. Epub 2017 Jul 25. No abstract available.

PMID:
28742453
3.

Genetics of gestational trophoblastic neoplasia: an update for the clinician.

Alifrangis C, Seckl MJ.

Future Oncol. 2010 Dec;6(12):1915-23. doi: 10.2217/fon.10.153. Review.

PMID:
21142864
4.

Outcomes of women diagnosed and treated for low-risk gestational trophoblastic neoplasia at the Queensland Trophoblast Centre (QTC).

Verhoef L, Baartz D, Morrison S, Sanday K, Garrett AJ.

Aust N Z J Obstet Gynaecol. 2017 Aug;57(4):458-463. doi: 10.1111/ajo.12622. Epub 2017 Mar 27.

PMID:
28345753
5.

Use of short tandem repeat analysis in unusual presentations of trophoblastic tumors and their mimics.

Aranake-Chrisinger J, Huettner PC, Hagemann AR, Pfeifer JD.

Hum Pathol. 2016 Jun;52:92-100. doi: 10.1016/j.humpath.2016.01.005. Epub 2016 Feb 4.

PMID:
26980014
6.

Optimal management of low-risk gestational trophoblastic neoplasia.

Goldstein DP, Berkowitz RS, Horowitz NS.

Expert Rev Anticancer Ther. 2015;15(11):1293-304. doi: 10.1586/14737140.2015.1088786. Epub 2015 Oct 30. Review.

PMID:
26517533
7.

Uterine artery pulsatility index improves prediction of methotrexate resistance in women with gestational trophoblastic neoplasia with FIGO score 5-6.

Sita-Lumsden A, Medani H, Fisher R, Harvey R, Short D, Sebire N, Savage P, Lim A, Seckl MJ, Agarwal R.

BJOG. 2013 Jul;120(8):1012-5. doi: 10.1111/1471-0528.12196. Epub 2013 Mar 21.

8.
9.

A successful pembrolizumab treatment case of lung adenocarcinoma after becoming resistant to ALK-TKI treatment due to G1202R mutation.

Shimada M, Tamura A, Yokosuka K, Kusaka K, Matsui H, Nagai H, Ohta K.

Respir Investig. 2018 Jul;56(4):365-368. doi: 10.1016/j.resinv.2018.04.004. Epub 2018 Jul 2.

PMID:
30008296
10.

Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia.

Winter MC, Tidy JA, Hills A, Ireson J, Gillett S, Singh K, Hancock BW, Coleman RE.

Gynecol Oncol. 2016 Dec;143(3):565-570. doi: 10.1016/j.ygyno.2016.10.001. Epub 2016 Oct 15.

PMID:
27756557
11.

The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease.

Goldstein DP, Garner EI, Feltmate CM, Berkowitz RS.

Gynecol Oncol. 2004 Dec;95(3):421-2. No abstract available.

PMID:
15581941
12.

Gestational trophoblastic neoplasia: where we came from, where we stand today, where we are heading. Keynote address.

Goldstein DP.

J Reprod Med. 2010 May-Jun;55(5-6):184-93. No abstract available.

PMID:
20626173
13.

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.

Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, McRee AJ, Lin CC, Pathiraja K, Lunceford J, Emancipator K, Juco J, Koshiji M, Bang YJ.

Lancet Oncol. 2016 Jun;17(6):717-726. doi: 10.1016/S1470-2045(16)00175-3. Epub 2016 May 3.

PMID:
27157491
14.

Prognosis of Patients with Gestational Trophoblastic Neoplasia and Obstetric Outcomes of Those Conceiving After Chemotherapy.

Gadducci A, Cosio S, Fanucchi A, Tana R, Manacorda S, Pistolesi S, Strigini FL.

Anticancer Res. 2016 Jul;36(7):3477-82.

PMID:
27354611
15.

Successful pregnancy after treatment of a cervical gestational trophoblastic neoplasia: a case report.

Chua AA, Soriano-Estrella AL.

J Reprod Med. 2012 Jan-Feb;57(1-2):85-8.

PMID:
22324277
16.

Postmolar choriocarcinoma: An independent risk factor for chemotherapy resistance in low-risk gestational trophoblastic neoplasia.

Strohl AE, Lurain JR.

Gynecol Oncol. 2016 May;141(2):276-280. doi: 10.1016/j.ygyno.2016.02.014. Epub 2016 Mar 3.

PMID:
26896825
17.

Effect of race/ethnicity on clinical presentation and risk of gestational trophoblastic neoplasia in patients with complete and partial molar pregnancy at a tertiary care referral center.

Gockley AA, Joseph NT, Melamed A, Sun SY, Goodwin B, Bernstein M, Goldstein DP, Berkowitz RS, Horowitz NS.

Am J Obstet Gynecol. 2016 Sep;215(3):334.e1-6. doi: 10.1016/j.ajog.2016.04.019. Epub 2016 Apr 26.

PMID:
27130239
18.

Gestational trophoblastic neoplasia.

Osborne R, Dodge J.

Obstet Gynecol Clin North Am. 2012 Jun;39(2):195-212. doi: 10.1016/j.ogc.2012.03.002. No abstract available.

PMID:
22640711
19.

Actinomycin D for methotrexate-failed low-risk gestational trophoblastic neoplasia.

Lurain JR, Chapman-Davis E, Hoekstra AV, Schink JC.

J Reprod Med. 2012 Jul-Aug;57(7-8):283-7.

PMID:
22838241
20.

Role of hysterectomy in the management of patients with gestational trophoblastic neoplasia: importance of receiving treatment in reference centers.

Pires LV, Uberti EM, Fajardo Mdo C, da Cunha AG, Rosa MW, Ayub AC, El Beitume P.

J Reprod Med. 2012 Jul-Aug;57(7-8):359-68.

PMID:
22838254

Supplemental Content

Support Center